Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study
- Registration Number
- NCT02520245
- Lead Sponsor
- Regeneron Pharmaceuticals
- Brief Summary
This study has been designed to collect long-term follow-up information for patients who received REGN2810 in other clinical studies and to allow re-treatment for eligible patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Not provided
A patient who meets any of the following criteria will be excluded from receiving re-treatment with REGN2810:
- Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for irAEs.
- Patients who experienced an irAE in while participating in another REGN2810 protocol who were unable to have their corticosteroid dose reduced to <10 mg per day prednisone equivalent within 12 weeks of toxicity.
- Patients who developed ≥ Grade 2 uveitis in a prior REGN2810 protocol
- Immunosuppressive corticosteroid doses (> 10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of REGN2810
- Active infection requiring therapy, including known infection with human immunodeficiency virus, or active infection with hepatitis B or hepatitis C virus.
- History of pneumonitis within the last 5 years.
- Any investigational or antitumor treatment within 30 days prior to the initial administration of REGN2810.
- History of documented allergic reactions or acute hypersensitivity reaction attributed of Grade ≥ 3 severity during or directly following an REGN2810 infusion
- Known allergy to doxycycline or tetracycline. (precaution due to presence of trace components in REGN2810)
- Breast-feeding
- Positive serum pregnancy test
- History within the last 5 years of an invasive malignancy other than the one treated in this study, with the exception of resected/ablated basal or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix, or other local tumors considered cured by local treatment.
- Acute or chronic psychiatric problems that, under the evaluation of the investigator, make the patient ineligible for participation
- Unwilling to practice adequate contraception during the study until 6 months after the last dose of study drug
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Open-Label REGN2810 -
- Primary Outcome Measures
Name Time Method Overall survival, from the first dose of study drug administered in the parent REGN2810 clinical study to death or date of last censoring up to 8 years Safety measured by the number of patients with AEs, AEs leading to discontinuation, SAEs, drug-related AEs, Immune-related adverse events (irAEs), and death as outcome. up to 8 years Safety includes the number of patients with AEs, AEs leading to discontinuation, SAEs, drug-related AEs, Immune-related adverse events (irAEs), and death as outcome.
- Secondary Outcome Measures
Name Time Method Duration of disease control (time from best overall response of SD as well as PR and CR to time to first do documented disease progression) up to 8 years Response duration (time from best overall response of partial or complete response, to time to first documented disease progression) up to 8 years
Trial Locations
- Locations (9)
City of Hope National Medical Center
🇺🇸Duarte, California, United States
Washington University School of Medicine Siteman Cancer Center
🇺🇸St. Louis, Missouri, United States
Laura & Isaac Perlmutter Cancer Center
🇺🇸New York, New York, United States
University Hospitals Case Medical Center
🇺🇸Cleveland, Ohio, United States
START South Texas Accelerated Research Therapeutics
🇺🇸San Antonio, Texas, United States
Stephenson Cancer Center
🇺🇸Oklahoma City, Oklahoma, United States
Sarah Cannon Research Institute at HealthONE
🇺🇸Denver, Colorado, United States
Providence Portland Medical Center
🇺🇸Portland, Oregon, United States
Sarah Cannon Research Institute
🇺🇸Nashville, Tennessee, United States